Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Established in 1996, the company is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. The firm’s biopharma facility in India is the first to be audited and approved by the Korean Food and Drug Administration. Bharat Biotech has set new benchmarks in innovation and quality that demonstrate the tremendous progress of Indian biotechnology in the global arena.
About 150 million doses of REVAC-B+TM (Hepatitis B vaccine) have been supplied by the company since its launch in 1998. The company is the largest primary manufacturer of Vi Capsular Polysaccharide Typhoid vaccine, TYPBARTM.
Bharat Biotech has commercialized India’s first recombinant epidermal growth factor, REGEN-DTM, to treat diabetic foot ulcers and burns. As one of the largest primary manufacturers of anti-rabies vaccines in India, the company produces INDIRABTM--a market leader in protection against infections from rabies.
The company’s strong pipeline includes proprietary vaccines and therapeutics for malaria, rotavirus, Japanese encephalitis, staph infections and thrombolytics. Bharat Biotech also performs contract development and manufacturing for western pharmaceutical and biotechnology companies.
IFC role and development impact:
- In 2005, IFC invested $4.5 million in equity to ?nance the company’s expansion program
- Modernization of manufacturing facilities to enable regulatory approvals for products designated for developed markets and to enter high-volume, donor-funded markets in developing countries
- Enhanced growth opportunities in domestic and international markets by expanding the company’s contract manufacturing and sales and marketing capabilities
- Investment in research and development through access to grant funding for new vaccine development
